Compare J M Smucker Co (SJM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs TransMedics Group Inc — how do they compare? J M Smucker Co trades at $112.69 (market cap $11.97B), while TransMedics Group Inc trades at $73.5 (market cap $2.54B). The key difference: J M Smucker Co is far larger — about 4.7× TransMedics Group Inc's market cap, and J M Smucker Co pays a 3.93% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| SJM | TMDX | |
|---|---|---|
Market Cap | $11.97B | $2.54B |
Sector | Consumer Staples | Technology |
52-Week High | $117.05 | $150.42 |
52-Week Low | $89.53 | $61.99 |
Enterprise Value | $19.00B | $2.94B |
Dividend Yield | 3.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $115.75, up 3.34% today, showing strong momentum near resistance levels. The company maintains positive cash flow despite recent net losses, with operating cash flow of $1.21 billion in 2025. Recent dividend increases and analyst consensus support a bullish outlook, though profitability metrics remain challenged with negative ROE and net margins. Technical indicators show bullish momentum with the stock trading above key moving averages.
The investment case balances strong cash generation and dividend growth against profitability challenges. Analyst consensus targets $125.50 with 52% buy ratings, suggesting 8.4% upside potential. Key risks include persistent negative margins, high debt levels at 43.7% debt-to-asset ratio, and competitive pressures in the consumer staples sector. The company's Uncrustables division remains a key growth driver with nearly $1 billion in annual sales.
TransMedics (TMDX) is trading at $73.47, down 0.69% on the day, amid a mixed technical and fundamental backdrop. The stock shows neutral technical signals with support near $72 and resistance at $75, while fundamentals are strong with a trailing P/E of 16.81 and robust profitability metrics like a 27.04% net income margin. Recent earnings saw a Q1 2026 miss but beats in prior quarters, and the company is expanding in Europe through strategic investments.
The outlook is cautiously optimistic with a consensus price target of $108.71 implying significant upside, supported by 75% analyst buy ratings. Key risks include margin pressure from expansion costs and competitive threats, but the company's organ transplant logistics network offers a durable competitive advantage for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
